Gender‐specific plasma proteomic biomarkers in patients with Anderson–Fabry disease. (23rd January 2015)

• Record Type: Journal Article
• Authors: Hollander, Zsuzsanna; Dai, Darlene L.Y.; Putko, Brendan N.; Yogasundaram, Haran; Wilson‐McManus, Janet E.; Thompson, Richard B.; Khan, Aneal; West, Michael L.; McManus, Bruce M.; Oudit, Gavin Y.
• Is Part Of: European journal of heart failure. Volume 17:Number 3(2015)
• Page Start: 291
• Page End: 300
• Publication Date: 2015-01-23
• Subjects: Heart failure -- Periodicals; Heart Failure -- Periodicals; Insuffisance cardiaque -- Périodiques; Heart failure; Periodicals; 616.129005
• DOI: 10.1002/ejhf.230
• Languages: English
• ISSNs: 1388-9842

Abstract

<abstract abstract-type="main" id="ejhf230-abs-0001"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="ejhf230-sec-0001" sec-type="section"> <title>Aims</title> <p id="ejhf230-para-0001">Anderson–Fabry disease (AFD) is an important X‐linked metabolic disease resulting in progressive end‐organ involvement, with cardiac disease being the dominant determinant of survival in a gender‐dependent manner. Recent epidemiological screening for AFD suggests the prevalence is much higher than previously recognized, with estimates of 1:3000. Our aim was to discover novel plasma biomarker signatures in adult patients with AFD.</p> </sec> <sec id="ejhf230-sec-0002" sec-type="section"> <title>Methods and results</title> <p id="ejhf230-para-0002">We used an unbiased proteomic screening approach to discover novel plasma biomarker signatures. In the discovery cohort of 46 subjects, 14 healthy controls and 32 patients with AFD, we used a mass spectrometry iTRAQ proteomic approach followed by multiple reaction monitoring (MRM) assays to identify biomarkers. Of the 38 protein groups discovered by iTRAQ, 18 already had existing MRM assays. Based on MRM, we identified an eight‐protein biomarker panel (22 kDa protein, afamin, α1 antichymotrypsin, apolipoprotein E, β‐Ala His dipeptidase, haemoglobin α‐2, isoform 1 of sex hormone‐binding globulin, and peroxiredoxin 2) that was very specific and sensitive for male AFD patients. In female AFD patients, we identified a nine‐marker panel of proteins with only three proteins, apolipoprotein E, haemoglobin α‐2, and peroxiredoxin 2, common to both genders, suggesting a gender‐specific alteration in plasma biomarkers in patients with AFD. The biomarkers were validated in plasma samples from 48 subjects using MRM, and they performed inferiorly in patients with heart failure.</p> </sec> <sec id="ejhf230-sec-0003" sec-type="section"> <title>Conclusions</title> <p id="ejhf230-para-0003">We have identified gender‐specific plasma protein biomarker panels that are specific and sensitive for the AFD phenotype. The gender‐specific panels offer important insight into potential differences in pathophysiology and prognosis between males and females with AFD.</p> </sec> </abstract>